| Names | |
|---|---|
| IUPAC name N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-phenylpropanoyl)amino]-10-(3-aminopropyl)-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChemSpider | |
| KEGG | |
PubChem CID | |
| |
| |
| Properties | |
| C50H67N11O11S2 | |
| Molar mass | 1062.27 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
CTOP is an opioid antagonist cyclic peptide related to somatostatin. [1] It has been used in research about other opioid ligands. [2] [3]
CTOP is described as a highly potent mu-opioid receptor antagonist. In mice, its analgesic effects are qualified as being more potent than naloxone's, a well-known opioid antagonist typically used as an antidote in humans. [4] Additionally, CTOP appears to lack significant affinity at the delta and kappa opioid receptors, suggesting that this peptide is selective for the µ receptor. [5]